These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://neilqwxi212022.is-blog.com/45964731/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide